Regenxbio (RGNX) EBIT Margin (2014 - 2025)

Regenxbio's (RGNX) quarterly EBIT Margin came in at 212.3% in Q4 2025, up 2984.0% year-on-year from 6.88% in Q4 2024, and down 20.44% quarter-over-quarter from 176.27% in Q3 2025.

Regenxbio (RGNX) EBIT Margin (2014 - 2025) Analysis & Trends

Regenxbio's EBIT Margin history runs 12 years deep, the most recent figure standing at 212.3% for Q4 2025.

  • On a quarterly basis, EBIT Margin rose 2984.0% year-over-year to 212.3% in Q4 2025; TTM through Dec 2025 was 97.52%, a 18497.0% increase from a year earlier, with the FY2025 full-year figure at 103.16%, up 17688.0% from the prior year.
  • EBIT Margin fell to 212.3% in Q4 2025 per RGNX's latest filing, from 176.27% in the prior quarter.
  • Across five years, EBIT Margin topped out at 78.66% in Q4 2021 and bottomed at 416.21% in Q1 2024.
  • The 5-year median for EBIT Margin is 239.58% (2021), against an average of 230.5%.
  • Across the five-year window, EBIT Margin sank 26297 bps in 2022 and surged 43014 bps in 2025, its largest moves.
  • Year by year, EBIT Margin stood at 78.66% in 2021, then plunged by 334 bps to 184.31% in 2022, then slumped by 56 bps to 287.68% in 2023, then increased by 16 bps to 242.14% in 2024, then gained by 12 bps to 212.3% in 2025.
  • Per Business Quant, the three latest RGNX EBIT Margin figures stand at 212.3% (Q4 2025), 176.27% (Q3 2025), and 296.26% (Q2 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBIT Margin (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 16.51%
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 38.10%
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 17.83%
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 31.68%
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Regenxbio 528.62 Mn 298.55 Mn 21.22 Mn -212.30%

Historic Data

Download Data
DateValue
Dec 31, 2025 -212.30%
Sep 30, 2025 -176.27%
Jun 30, 2025 -296.26%
Mar 31, 2025 13.93%
Dec 31, 2024 -242.14%
Sep 30, 2024 -256.55%
Jun 30, 2024 -256.51%
Mar 31, 2024 -416.21%
Dec 31, 2023 -287.68%
Sep 30, 2023 -224.67%
Jun 30, 2023 -365.96%
Mar 31, 2023 -345.68%
Dec 31, 2022 -184.31%
Sep 30, 2022 -267.97%
Jun 30, 2022 -191.53%
Mar 31, 2022 -321.93%
Dec 31, 2021 78.66%
Sep 30, 2021 -186.36%
Jun 30, 2021 -237.01%
Mar 31, 2021 -233.22%